Analyst Price Target is $4.38
▲ +9.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CRH Medical in the last 3 months. The average price target is $4.38, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 9.65% upside from the last price of $3.99.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in CRH Medical. This rating has held steady since February 2020, when it changed from a Buy consensus rating.
CRH Medical Corporation provides anesthesia services for patients undergoing endoscopic procedures in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology to treat various grades of hemorrhoid. The company also distributes CRH O'Regan system, treatment protocols, and operational and marketing expertise as a turnkey package directly to physicians. It serves 70 ambulatory surgical/endoscopy centers in 14 states. The company was formerly known as Medsurge Medical Products Corp. and changed its name to CRH Medical Corporation in April 2006. CRH Medical Corporation was founded in 2000 and is headquartered in Vancouver, Canada.